A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
dc.contributor.author | Heerspink, Hiddo J. L. | |
dc.contributor.author | Cherney, David | |
dc.contributor.author | Postmus, Douwe | |
dc.contributor.author | Stefánsson, Bergur V. | |
dc.contributor.author | Chertow, Glenn M. | |
dc.contributor.author | Dwyer, Jamie P. | |
dc.contributor.author | Greene, Tom | |
dc.contributor.author | Kosiborod, M. N. | |
dc.contributor.author | Langkilde, Anna-Maria | |
dc.contributor.author | McMurray, John J. | |
dc.contributor.author | Correa-Rotter, Ricardo | |
dc.contributor.author | Rossing, Peter | |
dc.contributor.author | Sjöström, C. David | |
dc.contributor.author | Toto, Roberto D. | |
dc.contributor.author | Wheeler, David C. | |
dc.contributor.author | Nagy, Gergely György | |
dc.date.accessioned | 2025-01-09T09:10:34Z | |
dc.date.available | 2025-01-09T09:10:34Z | |
dc.date.issued | 2022 | |
dc.date.oa | 2025-01-30 | |
dc.date.pasync | 2025-01-16T00:07:00Z | |
dc.date.updated | 2025-01-09T09:10:34Z | |
dc.description.corrector | kzs | |
dc.identifier.citation | Kidney International. -101 : 1 (2022), p. 174-184. -Kidney Int. - 0085-2538. - 1523-1755 | |
dc.identifier.doi | http://dx.doi.org/10.1016/j.kint.2021.09.005 | |
dc.identifier.issn | 0085-2538 | |
dc.identifier.issn | 1523-1755 | |
dc.identifier.opac | https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM126505 | |
dc.identifier.scopus | 85120341223 | |
dc.identifier.uri | https://hdl.handle.net/2437/384681 | |
dc.identifier.url | https://linkinghub.elsevier.com/retrieve/pii/S0085253821008656 | |
dc.identifier.wos | 000753363800021 | |
dc.language | eng | |
dc.rights.access | open access article | |
dc.rights.owner | szerző | |
dc.subject.mab | Orvostudományok | |
dc.subject.mab | Klinikai orvostudományok | |
dc.title | A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function | |
dc.type | folyóiratcikk | |
dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- FILE_UP_0_Heerspink2022_KidneyInt_A pre-specified analysis of the dapagliflozin.pdf
- Méret:
- 748.9 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- kiadói változat